Dec 30, 2004|
Pharma: Opportunity looms large
The year 2004 was another ‘special’ year for the stock market participants, as the markets see-sawed towards their all time high levels. While almost all the sectors participated in the bull-run, pharma stocks were among the leaders, again outperforming the broader indices after the strong performance in 2003. Against 14% gains for the Sensex, the pharma index gained 20% during the year.
The year started well for the industry with robust growth witnessed during the first quarter. A major growth driver for the industry once again was new products introduction as companies tried their hands out on various kinds of products in order to capture largest market share before the new patent regime comes into picture.
| What was different in 2004 as compared to 2003?|
The growth in the domestic market was sluggish while revenues from international markets grew at a rapid pace for Indian companies. According to the statistics of Ministry of Chemicals and Fertilizers, export revenues from the pharmaceutical sector are likely to grow at a CAGR of 30% over the next three years (including FY05). The year saw smaller companies like Matrix labs and Divi’s Labs made their way further into exports markets.
MNC pharma companies were the biggest gainers during 2004 with Aventis emerging the leader. There were two reasons for this out-performance by Aventis. While the performance of the company was very good on profitability front, the markets have also taken a re-look at the valuations. Somewhat similar was the case with other major MNC pharma companies like Glaxo and Novartis. While Novartis saw a rise in its stock price after the announcement by the company that it will try to reach out into a larger part of India. The company has plans to introduce new drugs once the product patent comes into force.
| The sector outperformer: Aventis |
Apart from the MNC pharma companies, Nicholas Piramal was amongst the major gainers in the sector. Two important events that marked the year for Nicholas Piramal were the contract manufacturing business picking pace, as well the investment in R&D. The company started a new R&D center with a capital expenditure of about Rs 1 bn making it one of the biggest R&D center in private sector. On the contract manufacturing side, the company was able to enter into three agreements for custom manufacturing of different products. The total size of the three deals is about US$ 50 m which is equal to about 20% of the company’s current revenue.
Despite the strong performance of the overall market, including stocks from the pharma sector, leading Indian player, Dr. Reddy’s witnessed a decline in 2004. The year started on a bad note for the company as a US federal court reversed the lower court decision by its verdict saying that the company’s generic version ‘Amolodipine Maleate’ will infringe upon the patent of Pfizer’s ‘Norvasc’. To add on to this, in the first quarter of 2004, the company also reported operating losses. The dismal performance continued for the rest of the year. Higher sales and distribution and R&D expanses led to the declining margins for the company.
In another important event from the sector, India’s largest biotech company, Biocon, came up with its initial public offering. The biggest event of the year, however, which was keenly awaited both by the industry as well as the markets, was the introduction of the new patent regime. Although, a change in government earlier in the year meant that the new government was not ready with a fresh bill, and hence the recently issued ordinance in order to comply to the WTO regulations. The ordinance on patent (third) amendment act meant that India would transform into the era where the intellectual property rights will be respected and will have a legal framework for enforcement.
The year 2004 was an eventful year with new companies entering into the bandwagon for pharma exports. However, 2005 is likely to be ‘the’ year of execution for most of the companies. As far as the domestic markets are concerned, the patent ordinance will definitely instill confidence among players in the industry. However, we may not see a sudden jump in revenues and profits of MNC companies as they may approach new product launches with caution.
On the exports front, the US government has intensified its efforts towards usage of generics drugs. Drugs worth US$ 35 billion are going off patent in the next three years and Indian companies are likely to be the biggest beneficiaries of the same. While Indian companies like Ranbaxy, Sun Pharma, Lupin Labs and Dr. Reddy’s are likely to get the benefits directly they might feel competitive pressures as MNC players are sourcing their drugs from India thus reducing the costs. 2005 is, thus, likely to witness greater global acceptance of India as a pharmaceutical power to reckon with!
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407